Shanghai Jiatan Pharmatech Co., Ltd
11
5
5
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
18%
2 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment
Role: lead
A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients
Role: lead
Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults
Role: lead
A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations
Role: lead
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Role: lead
Pharmacokinetic Study of Sudapyridine（WX-081）in Healthy Chinese Subjects
Role: lead
A Study of WX390 in Patients With Advanced Solid Tumors
Role: lead
A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations
Role: lead
Sudapyridine (WX-081) in Healthy Volunteers
Role: lead
Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081
Role: lead
A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma
Role: lead
All 11 trials loaded